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Alzheimer's disease (AD) is pathologically characterized by senile plaques, largely composed of extracellular deposits of A3 peptide, and neurofibrillary tangles (NFTs), composed of intracellular filamentous aggregates of hyperphosphorylated tau protein. Since the initial molecular characterizations of these lesions (1-3), there has been controversy over how these lesions and their constituent molecules are pathogenically related to each other and to the neuronal and synaptic losses that characterize the disease (4-6). A key part of this debate has been the observation that the pathogenic mutations that underlie the autosomal dominant forms of the disease-mutations in APP or in the presenilins PS-1 and PS-2 (7-9)-lead to increased production of the AP42 peptide in tissues from affected individuals (10), in transfected cells (11) (12) (13) , and in transgenic animals (12, 14-18). Some transgenic mouse models for AD, overexpressing mutant human APP alone or Birdsall Building, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA. *These authors contributed equally to this report. tTo whom correspondence should be addressed. Email: hutton.michael@mayo.edu Alzheimer's disease (AD) is pathologically characterized by senile plaques, largely composed of extracellular deposits of A3 peptide, and neurofibrillary tangles (NFTs), composed of intracellular filamentous aggregates of hyperphosphorylated tau protein. Since the initial molecular characterizations of these lesions (1-3), there has been controversy over how these lesions and their constituent molecules are pathogenically related to each other and to the neuronal and synaptic losses that characterize the disease (4-6). A key part of this debate has been the observation that the pathogenic mutations that underlie the autosomal dominant forms of the disease-mutations in APP or in the presenilins PS-1 and PS-2 (7-9)-lead to increased production of the AP42 peptide in tissues from affected individuals (10), in transfected cells (11) (12) (13) , and in transgenic animals (12, 14-18). Some transgenic mouse models for AD, overexpressing mutant human APP alone or Birdsall Building, Mayo Clinic Jacksonville, 4500 San Pablo Road, Jacksonville, FL 32224, USA. *These authors contributed equally to this report. tTo whom correspondence should be addressed. Email: hutton.michael@mayo.edu with mutant PS-1, develop senile plaques; however, these mice lack NFTs and exhibit little neuronal loss (14-18). This has limited their use as models of disease and fueled the notion that senile plaques and NFTs are generated by independent processes. Neurofibrillary pathology is also a feature of other neurodegenerative diseases, including FTDP-17 (frontotemporal dementia and Parkinsonism linked to chromosome 17). Mutations in the tau gene underlie FTDP-17, hence tau dysfunction is sufficient to cause neurodegeneration (19). Furthermore, JNPL3 transgenic mice with the Pro301 --Leu (P301L) tau mutation develop NFTs in the basal telencephalon, diencephalon, brainstem, and spinal cord, along with neuronal loss that is most evident in the spinal cord, especially in the anterior hor (20).
The production of these mutant tau transgenic mice provided the opportunity to test experimentally whether the distribution or timing of neurofibrillary pathology is influenced by the pathogenic mutations that cause AD. Therefore, we crossed Tg2576 transgenic mice expressing the APPsw mutation (Lys670 ---Asn, Met671 -> Leu) (15, 21, 22) with JNPL3 transgenic mice expressing muwith mutant PS-1, develop senile plaques; however, these mice lack NFTs and exhibit little neuronal loss (14-18). This has limited their use as models of disease and fueled the notion that senile plaques and NFTs are generated by independent processes. Neurofibrillary pathology is also a feature of other neurodegenerative diseases, including FTDP-17 (frontotemporal dementia and Parkinsonism linked to chromosome 17). Mutations in the tau gene underlie FTDP-17, hence tau dysfunction is sufficient to cause neurodegeneration (19). Furthermore, JNPL3 transgenic mice with the Pro301 --Leu (P301L) tau mutation develop NFTs in the basal telencephalon, diencephalon, brainstem, and spinal cord, along with neuronal loss that is most evident in the spinal cord, especially in the anterior hor (20).
The production of these mutant tau transgenic mice provided the opportunity to test experimentally whether the distribution or timing of neurofibrillary pathology is influenced by the pathogenic mutations that cause AD. Therefore, we crossed Tg2576 transgenic mice expressing the APPsw mutation We examined the brains and spinal cords of Tg2576 X JNPL3 progeny at 2.5 to 3.5 months, 6 to 7 months, and 8.5 to 15 months of age (24-29). These progeny included double mutant tau (P301L)-mutant APP (APPsw) (hereafter termed TAPP mice), mutant tau (JNPL3), mutant APP (Tg2576), and nontransgenic animals. TAPP mice had amyloid plaques similar in number and distribution to those of comparably aged Tg2576 mice. Plaques were detected as early as 6 months of age but became numerous only in older TAPP and Tg2576 mice (8.5 to 15 months) in the olfactory cortex, cingulate gyrus, amygdala, entorhinal cortex, and hippocampus ( Fig. 1) (30) . NFTs were morphologically similar in TAPP and JNPL3 mice and appeared in the spinal cord and pons as early as 3 months of age, but were consistently present and numerous only in older animals ( Figs. 2 and 3) . Some of the NFTs were fluorescent when stained with thioflavin-S, and all were intensely positive for Gallyas silver stain and immunoreactive with a panel of antibodies to tau protein, including antibodies to phosphorylation-dependent and conformational epitopes (24-28) (Fig. 1) . Ultrastructurally, NFTs in the TAPP mice were also similar to those in JNPL3 mice and were composed of straight filaments, 17 to 22 nm We examined the brains and spinal cords of Tg2576 X JNPL3 progeny at 2.5 to 3.5 months, 6 to 7 months, and 8.5 to 15 months of age (24-29). These progeny included double mutant tau (P301L)-mutant APP (APPsw) (hereafter termed TAPP mice), mutant tau (JNPL3), mutant APP (Tg2576), and nontransgenic animals. TAPP mice had amyloid plaques similar in number and distribution to those of comparably aged Tg2576 mice. Plaques were detected as early as 6 months of age but became numerous only in older TAPP and Tg2576 mice (8.5 to 15 months) in the olfactory cortex, cingulate gyrus, amygdala, entorhinal cortex, and hippocampus ( Fig. 1) (30) . NFTs were morphologically similar in TAPP and JNPL3 mice and appeared in the spinal cord and pons as early as 3 months of age, but were consistently present and numerous only in older animals (Figs. 2 and 3) . Some of the NFTs were fluorescent when stained with thioflavin-S, and all were intensely positive for Gallyas silver stain and immunoreactive with a panel of antibodies to tau protein, including antibodies to phosphorylation-dependent and conformational epitopes (24-28) (Fig. 1) Although NFTs were morphologically similar in the TAPP and JNPL3 (mutant tau) mice, older female TAPP mice (9 to 11 months) had a marked increase in NFTs in limbic areas, most notably the olfactory cortex, entorhinal cortex, and amygdala. This enhanced neurofibrillary degeneration occurred as early as 6 months of age. The density of NFTs in these regions in female TAPP mice (9 to 11 months) was greater than in female JNPL3 littermates by a factor of more than 7 (P < 0.012 to P < 0.0009) (Figs. 2 and 3). NFTs were also detected in the subiculum, hippocampus, and occasionally isocortex in the TAPP animals, areas that rarely or never had NFTs in JNPL3 mice. The number and distribution of pretangles was also increased in female TAPP mice (9 to 11 months) in limbic areas and cerebral cortex. In contrast, subcortical neurofibrillary pathology was similar in female TAPP and JNPL3 mice, with no increase in density of either NFTs or pretangles in the diencephalon, hindbrain, or spinal cord (Fig. 3 ). NFTs and pretangles were not observed in the basal ganglia in TAPP mice. In limbic areas with the most NFTs, there was a concomitant increase in astrocytosis (Fig. 2) in TAPP mice. In contrast, in the ventral diencephalon, hindbrain, and spinal cord of JNPL3 and TAPP mice, gliosis was equally severe. Enhanced neurofibrillary pathology in female TAPP mice (9 to 11 months) in limbic regions is of interest because these are the areas in which AP pathology first develops in Tg2576 mice (15).
However, even in areas vulnerable to both types of lesions (such as the entorhinal cortex), NFTs were not typically increased in the immediate vicinity of amyloid deposits. The fact that amyloid plaques were not generally surrounded by tangle-bearing neurons suggests that either a high-AP environment or APP dysfunction, but not necessarily the formation of mature amyloid deposits, is responsible for the modulation and enhancement of the tau phenotype in the TAPP mice. Interestingly, male TAPP mice did not develop similar enhanced NFT pathology in limbic regions (Fig. 3) . This likely reflects sex differences in the development of NFT pathology previously observed in the JNPL3 line; female mice develop NFT pathology significantly earlier than do males (32). However, the difference between female and male TAPP mice could also be caused by significant sex differences in amyloid burden previously noted in older Tg2576 mice (33) or could reflect hormonal changes in aging female TAPP mice. The latter possibility is interesting given the higher incidence of AD in women (34-36).
The morphology, distribution, and density of the amyloid plaques were similar in TAPP mice and age-matched Tg2576 mice (Fig. 1)  (30) . The amyloid deposits were immunoreactive for both A140 and Ap42 (30). In addition, dystrophic neurites immunoreactive for APP were associated with the senile plaques in both TAPP and Tg2576 mice (30). Some of the plaques had neurites that were immunoreactive with phospho-tau antibodies, but plaque-associated neurites were not detected with antibodies specific to conformational tau epitopes, such as Alz50 and MC1, or antibodies specific to NFTs, such as Ab39 (Fig. 1) (30) . To date, we have not identified plaque-associated dystrophic neurites containing tau-immunoreactive filamentous structures at the ultrastructural level.
Brain A3 (C), 200x; (B), (D), and (F), 400x. the TAPP mice compared with Tg2576 mice at the same age. A larger series of animals, however, will be needed to determine whether there are significant differences in the initial levels of AP in young TAPP mice and in the rate of A3 deposition as the mice age.
Levels of total soluble endogenous and transgenic tau protein (40) and tau mRNA (41) were similar in TAPP and JNPL3 brains (30). In addition, in situ hybridization analysis showed no difference in tau transgene expression pattern between TAPP and JNPL3 mice. These data indicate that there was no global or region-specific increase in tau expression that could explain the enhanced neurofibrillary pathology in the TAPP mice.
Sarkosyl-insoluble tau extracted from both TAPP and JNPL3 mice contained a major hyperphosphorylated species migrating at 64 kD (Fig. 3) however, enhanced insoluble tau in the cortex/limbic fraction was not observed in TAPP mice. This correlates with the observation that significant increases in limbic NFT pathology are detected only after 9 months in female TAPP mice (Fig. 3) . In addition to increased NFTs, granulovacuolar degeneration was observed in neurons in the amygdala, entorhinal cortex, and subiculum in female TAPP mice (Fig. 1) 
